<?xml version="1.0" encoding="UTF-8"?>
<p id="para540">An adverse cytogenetic profile is a major risk factor for relapse, and outcomes for patients with high-risk cytogenetics are poor.
 <xref rid="bib1" ref-type="bibr">1</xref>, 
 <xref rid="bib3" ref-type="bibr">3</xref>, 
 <xref rid="bib28" ref-type="bibr">28</xref> Data supporting the use of lenalidomide maintenance in patients with adverse cytogenetics are scarce, and results thus far have been inconclusive. In the IFM-2005-02 trial,
 <xref rid="bib7" ref-type="bibr">
  <sup>7</sup>
 </xref> lenalidomide maintenance therapy improved median progression-free survival in patients with del(17p) compared with observation (29 months 
 <italic>vs</italic> 14 months), whereas those with t(4;14) did not have a benefit (28 months 
 <italic>vs</italic> 24 months), probably because of the small sample size.
</p>
